Definium Therapeutics (DFTX) Other Non Operating Income (2019 - 2026)
Definium Therapeutics (DFTX) reported Other Non Operating Income of -$17.9 million for Q1 2026, down 93994.74% year-over-year from N/an in Q1 2025, and down 13547.33% quarter-over-quarter from -$131000.0 in Q4 2025.
Definium Therapeutics (DFTX) Other Non Operating Income (2019 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 7 years of Other Non Operating Income data on file, last reported at -$17.9 million in Q1 2026.
- Other Non Operating Income for Q1 2026 came in at -$17.9 million, down 93994.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$39.7 million (down 214.22% YoY), and the FY2025 annual result was -$131000.0, down 105.16% from the prior year.
- Other Non Operating Income fell to -$17.9 million in Q1 2026 per DFTX's latest filing, from -$131000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $18.6 million in Q2 2024 and troughed at -$32.2 million in Q1 2024.
- A 5-year average of -$1.9 million and a median of $54000.0 in 2022 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2026: Other Non Operating Income soared 7431.98% in 2024, then slumped 93994.74% in 2026.
- A 5-year view of Other Non Operating Income shows it stood at $101000.0 in 2022, then soared by 141.58% to $244000.0 in 2023, then jumped by 1959.43% to $5.0 million in 2024, then plunged by 102.61% to -$131000.0 in 2025, then plunged by 13547.33% to -$17.9 million in 2026.
- Business Quant data shows DFTX's Other Non Operating Income at -$17.9 million in Q1 2026, -$131000.0 in Q4 2025, and -$21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.88 Mn |
| Dec 31, 2025 | -131,000.00 |
| Sep 30, 2025 | -21.60 Mn |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -19,000.00 |
| Dec 31, 2024 | 5.03 Mn |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 18.60 Mn |
| Mar 31, 2024 | -32.20 Mn |
| Dec 31, 2023 | 244,000.00 |
| Sep 30, 2023 | 3.69 Mn |
| Jun 30, 2023 | 247,000.00 |
| Mar 31, 2023 | -52,000.00 |
| Dec 31, 2022 | 101,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -180,000.00 |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -35,000.00 |